Abstract
AbstractNot all MET exon 14 skipping (METex14) NSCLC patients benefited from MET inhibitors. We hypothesized an inter-tumoral heterogeneity in METex14 NSCLC. Investigations at genomic and transcriptomic level were conducted in METex14 NSCLC samples from stage I-III and recurrent/metastatic patients as discovery and validation cohort. Four molecular subtypes were discovered. MET-Driven subtype, with the worst prognosis, displayed MET overexpression, enrichment of MET-related pathways, and higher infiltration of fibroblast and regulatory T cells. Immune-Activated subtype having the most idea long-term survival, had higher tertiary lymphoid structures, spatial co-option of PD-L1+ cancer cells, and GZMK+ CD8+ T cell. FGFR- and Bypass-Activated subtypes displayed FGFR2 overexpression and enrichments of multiple oncogenic pathways respectively. In the validation cohort, patients with MET-Driven subtype had better response to MET inhibitors than those with MET overexpression. Thus, molecular subtypes of METex14 NSCLC with distinct biological and clinical significance may indicate more precise therapeutic strategies for METex14 NSCLC patients.
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference65 articles.
1. Li, S. et al. Comprehensive characterization of oncogenic drivers in Asian Lung Adenocarcinoma. J. Thorac. Oncol. 11, 2129–2140 (2016).
2. Lee, G. D. et al. MET Exon 14 skipping mutations in Lung Adenocarcinoma: Clinicopathologic implications and prognostic values. J. Thorac. Oncol. 12, 1233–1246 (2017).
3. Frampton, G. M. et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 5, 850–859 (2015).
4. Schrock, A. B. et al. Characterization of 298 patients with lung cancer harboring MET Exon 14 Skipping Alterations. J. Thorac. Oncol. 11, 1493–1502 (2016).
5. Wolf, J. et al. Capmatinib in MET Exon 14-mutated or MET-amplified non-small-cell lung cancer. N. Engl. J. Med. 383, 944–957 (2020).